Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant

Breast Cancer Clinical Trial

Official title:

Open-Label Single-Arm Pilot Study of Deferasirox (Exjade®) in Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients With Transfusional Iron Overload

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00602446
• Other study ID #: CDR0000584690
• Secondary ID: UMN-2007LS065UMN
• Status: Terminated
• Phase: Phase 2
• First received: January 24, 2008
• Last updated: December 3, 2017
• Start date: August 2007
• Est. completion date: December 2009

Study information

• Verified date: December 2017
• Source: Masonic Cancer Center, University of Minnesota
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

RATIONALE: Deferasirox may be effective in treating iron overload caused by blood transfusions in patients who have undergone donor stem cell transplant.

PURPOSE: This phase II trial is studying the side effects and how well deferasirox works in treating patients with iron overload after donor stem cell transplant.

Description:

OBJECTIVES:

Primary

• To evaluate the safety of deferasirox given over 6 months in reducing liver iron concentration in patients with transfusional iron overload after undergoing allogeneic hematopoietic stem cell transplantation.

Secondary

• To evaluate the efficacy of deferasirox in reducing liver iron overload in these patients.

OUTLINE: This is a multicenter study.

Patients receive oral deferasirox once daily for 6 months in the absence of disease progression or unacceptable toxicity.

After completion of study therapy, patients are followed at 4 weeks.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 4
• Est. completion date: December 2009
• Est. primary completion date: September 2009
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Confirmed diagnosis of iron overload, defined as serum ferritin > 1,000 ng/mL and liver iron concentration = 5 mg iron/g on tissue proton transverse relaxation rates Magnetic Resonance Imaging (MRI)

• Underwent prior allogeneic hematopoietic stem cell transplantation (HSCT) using either myeloablative or reduced-intensity conditioning at least 12 months ago

• No evidence of relapse or progression of the primary disease for which allogeneic HSCT was performed

• Patients who have become red-cell transfusion independent (i.e., no red cell transfusions within the past 3 months) as well as patients who require red cell transfusions are eligible

• Meets one of the following criteria:

• Ineligible for phlebotomy (hemoglobin < 11 g/dL, poor intravenous access, or unable to undergo phlebotomy every 4 weeks)

• Have failed treatment with phlebotomy (serum ferritin > 50% of baseline after 3 months of phlebotomy)

• Refused phlebotomy

• ECOG performance status of 0-2

• Life expectancy = 6 months

• Adequate renal function defined as serum creatinine < or = 1.6 mg/dL and creatinine clearance of > or = 60 ml/min calculated using the Crockcroft-Gault formula on 2 occasions within 30 days of enrollment

• Sexually active men and women must use an effective method of contraception. Alternatively, women must have undergone clinically documented total hysterectomy and/or oophorectomy, or tubal ligation or be postmenopausal.

• Must be able to give written informed consent.

• Prior therapy with deferoxamine allowed provided it was completed = 12 months ago

Exclusion Criteria:

• Contraindication for performing MRI or inability to undergo MRI because of claustrophobia or weight (>350 pounds).

• Inability to take medications orally.

• Uncontrolled bacterial, viral, or fungal infection

• ANC = 1,000/mm³

• Hemoglobin = 8.0 g/dL

• Platelet count = 50,000/mm³

• Aspartate aminotransferance (AST) and alanine aminotransferase (ALT) = 5 times the upper limit of normal

• Less than 4 weeks since prior and no concurrent systemic investigational drug

• Less than 7 days since prior and no concurrent topical investigational drug. Concurrent non-investigational medications needed to treat concomitant medical conditions are allowed, with the exception of other chelating agents. Concurrent growth factors such as epoetin alfa, darbepoetin alfa, filgrastim (G-CSF), and sargramostim (GM-CSF) allowed. Concurrent irradiated packed red-cell and platelet transfusions allowed as clinically indicated. Concurrent low-doses of vitamin C supplements (= 200 mg/day) allowed.

• Concurrent iron supplements or multivitamins with iron.

• Aluminum-containing antacid therapies may not be taken simultaneously with deferasirox, but may be taken 2 hours before or after administration of deferasirox

• On dialysis or status post-renal transplantation

• Pregnant or nursing

Related Conditions & MeSH terms

• Breast Cancer
• Iron Overload
• Leukemia
• Lymphoma
• Multiple Myeloma
• Multiple Myeloma and Plasma Cell Neoplasm
• Myelodysplastic Syndromes
• Neoplasms, Plasma Cell
• Neuroblastoma
• Ovarian Cancer
• Plasmacytoma
• Preleukemia

Intervention

Drug:
• deferasirox
20 mg/kg once daily orally for 6 months

Locations

Country	Name	City	State
United States	Masonic Cancer Center at University of Minnesota	Minneapolis	Minnesota

Sponsors (1)

Lead Sponsor	Collaborator
Masonic Cancer Center, University of Minnesota

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Patients Not Completing Treatment	Number of patients who discontinued deferasirox during 6 month daily treatment due to drug related toxicity	6 Months
Secondary	Reduction in Liver Iron Concentration After Study Drug	Efficacy as measured by reduction in liver iron concentration (LIC) after 6 months of the study drug compared to baseline (LIC at baseline minus LIC at 6 months). This shows the mean reduction for the 3 subjects treated in this study.	6 Months